2021
Influenza Antiviral Treatment and Length of Stay
Campbell AP, Tokars JI, Reynolds S, Garg S, Kirley PD, Miller L, Yousey-Hindes K, Anderson EJ, Oni O, Monroe M, Kim S, Lynfield R, Smelser C, Muse AT, Felsen C, Billing LM, Thomas A, Mermel E, Lindegren ML, Schaffner W, Price A, Fry AM. Influenza Antiviral Treatment and Length of Stay. Pediatrics 2021, 148: e2021050417. PMID: 34470815, DOI: 10.1542/peds.2021-050417.Peer-Reviewed Original ResearchConceptsLaboratory-confirmed influenzaAntiviral treatmentMedical conditionsHospitalized patientsIllness onsetHigh-risk medical conditionsInfluenza Hospitalization Surveillance NetworkKaplan-Meier survival analysisEarly antiviral treatmentEmpiric antiviral treatmentInfluenza antiviral treatmentLength of stayHospital lengthICU cohortMedian LOSSymptom onsetShorter hospitalizationPrevention recommendationsTime-dependent variablesCox modelAntiviral agentsSurvival analysisCohortDisease controlInfluenza
2012
Reduced Influenza Antiviral Treatment Among Children and Adults Hospitalized With Laboratory-Confirmed Influenza Infection in the Year After the 2009 Pandemic
Garg S, Chaves SS, Pérez A, D'Mello T, Gershman K, Meek J, Yousey-Hindes K, Arnold KE, Farley MM, Tengelsen L, Ryan P, Sharangpani R, Lynfield R, Morin C, Baumbach J, Hancock EB, Zansky S, Bennett NM, Fowler B, Bradley K, Thomas A, Cooper T, Schaffner W, Boulton R, Finelli L, Fry AM. Reduced Influenza Antiviral Treatment Among Children and Adults Hospitalized With Laboratory-Confirmed Influenza Infection in the Year After the 2009 Pandemic. Clinical Infectious Diseases 2012, 55: e18-e21. PMID: 22543024, DOI: 10.1093/cid/cis442.Peer-Reviewed Original Research